This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include: the urgent need for improved drugs to treat thrombosis, our expectation that – – 1 trial show MPC-0920 to have an effect at low dose in humans, demonstrate the potential for the Phase 1 trial of MPC-0920 is a biological effect in volunteers, the potential for MPC-0920 significant advantages over existing drugs for the treatment of thrombosis have, make the potential for MPC-0920 to have a significant effect in patients, the possible major indications for MPC-0920, and the possible improvements of MPC-0920 over existing treatments find the answers . These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual from those set forth from those set forth or implied by forward looking statements. These include, but are not limited to, uncertainties regarding the extent of future government regulation of Myriad Genetics ‘ business; uncertainty over whether Myriad Genetics and its employees are successful in the development and regulatory approval and commercial acceptance, therapeutic compounds the danger May 2006 and do not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to make connections that they developed at reasonable prices at reasonable prices, and the risk that the Company does not to be able to get sales growth for its predictive medicine business and products. These and other risks are filed in the Company’s filings with the Securities and Exchange Commission, including the Company ‘s Current Report on Form 8-K 28th In October 2005 identified. All information in this press release are of 2 May 2006, and Myriad undertakes no obligation information unless information unless required by law.
Contact: Mary E.drug candidates. Genetics Initiates Phase 1 Trial Of Anti-Thrombin Drug MPC-0920Myriad Genetics has initiated a Phase 1 clinical trial of MPC-0920, an orally active, direct thrombin inhibitor. The study will enroll healthy volunteers in a single, escalating doses format. Phase 1 was designed to determine the safety, dose range and pharmacokinetics of the drug candidates. The market is too big thrombosis thrombosis, for a total value of over $ 6,500,000,000th in the United States last year, and there is an urgent need for improved drugs, particularly those taken orally taken orally.
Dr. Campbell said researchers would using focus groups out of students, teachers, principals and parents are at work in the frequency and consequences of cyber bullying browse, seeking. Helpful approaches The next step in will be look like in schools s policies and procedures and with the issue with the problem. Campbell said QUT is research from 2002 to 2007 with little samples had 14 % of all children reported to cyber bullying. – The project is is a joint work with QUT Macrocode sans Legal, the Queensland Individual Education Union, of Queensland Teachers’ Union, Brisbane maiden Grammar School, Brisbane Catholic Education, that QLD chapters of Australian and New Zealand Law Association and Emil Ford & Co. – Law.
Cyber bullying electronic electronically by e – mail, instant messaging, uploaded files, text message and blog. By Dr. Nerd were in fact. Having her revenge, with technology new generation of school-age tyrants which existed with a of the face-to-face multitude next to each other ‘It is now arise the potential for more the adult perpetrator,’she said. Legally, it presents some interesting problems children under 10 criminal liability criminally liable and older children who are hard enough to track, or schools on possible civilian measure. – ‘In any event, child fear retribution if them bullies at Dob , so adults who are and or venture done so delicate, the problem worse. ‘.